Heteroaryl substituted pyridyl compounds useful as kinase modulators

US10023562B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Rajeev S. Bhide · Princeton Junction, US
• John V. Duncia · Newtown, US
• John Hynes · Washington Crossing, US
• Satheesh Kesavan Nair · Kanchinakote, IN
• William J. Pitts · Newtown, US
• Sreekantha Ratna Kumar · Bengaluru, IN
• Daniel S. Gardner · Furlong, US
• Natesan Murugesan · Lawrenceville, US
• Venkatram Reddy Paidi · Bengaluru, IN
• Joseph B. Santella · Springfield, US
• Ramesh Kumar Sistla · Bengaluru, IN
• Hong Wu · Meekrap-oord, CN

Key dates

• Filing date: Apr 6, 2017
• Grant date: Jul 17, 2018
• Expiry date: Apr 6, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.